Clinical Observation of Addition and Subtraction Therapy of Danggui Shaoyaosan Combined with Huaihuasan to Ulcerative Colitis with Syndrome of Dampness-heat in Large Intestine During Active Stage
10.13422/j.cnki.syfjx.20191832
- VernacularTitle: 当归芍药散合槐花散加减治疗溃疡性结肠炎活动期大肠湿热证的临床观察
- Author:
Fang LIU
1
;
Na LEI
2
;
Xue-gui TANG
1
Author Information
1. The Affiliated Hospital of North Sichuan Medical College, Nanchong 637001, China
2. Chengdu University of Traditional Chinese Medicine, Chengdu 610015, China
- Publication Type:Research Article
- Keywords:
ulcerative colitis;
dampness-heat in large intestine;
simultaneous treatment of Xue and Shui;
Danggui Shaoyaosan;
Huaihuasan;
braingut petide neurotransmitter;
inflammatory cytokines
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(20):82-87
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the effects of addition and subtraction therapy of Danggui Shaoyaosan combined with Huaihuasan on ulcerative colitis (UC) with syndrome of dampness-heat in large intestine during active stage, and the effects on brain-gut petide neurotransmitter and inflammatory cytokines. Method:A total of 130 cases were included and randomly divided into control group and observation group, 65 cases in each group. In the control group, the patients received oral administration of mesalazine enteric-coated tablets, 1.0 g/time and 3 times/days. Severe patients received prednisone acetate tablets (0.75 mg·kg-1·d-1) in several times by oral administration. Based on the treatment in control group, patients in observation group also received addition and subtraction therapy of Danggui Shaoyaosan combined with Huaihuasan, 1 dose/day. Both groups were treated for 4 weeks. Symptom scores, Mayo scores, colonic mucosa scores and Inflammatory Bowel Disease Questionnaire (IBDQ) scores were assessed before and after treatment. Patients in remission stage were followed up for 6 months to record the recurrence. Before and after treatment, vasoactive intestinal peptide (VIP), substance P (SP), somatostatin (SS), interleukin-1 (IL-1), IL-6, IL-4 and IL-10 were detected. Result:After 4 weeks of treatment, the clinical remission rate was 93.22%in the observation group, better than 80.7%in the control group (χ2=4.035,P<0.05). The scores of various symptoms in the observation group were lower than those in the control group (P<0.01). The Mayo scores and colonic mucosal scores in the observation group were lower than those in the control group (P<0.01). The IBDQ scores in all dimensions and the total IBDQ scores in the observation group were higher than those in the control group (P<0.01). In 6 months of follow up for the patients in clinical remission stage, the recurrence rate in the observation group was 18.18%, lower than 36.96%in the control group (χ2=4.509,P<0.05), and the recurrence time was longer than that in the control group (P<0.01). The levels of serum IL-1 and IL-6 in the observation group were lower than those in the control group (P<0.01), and the levels of IL-4 and IL-10 were higher than those in the control group (P<0.01). Plasma VIP and SS levels in the observation group were higher than those in the control group (P<0.01), while SP levels were lower than those in the control group (P<0.01). Conclusion:On the basis of conventional western medicine treatment, addition and subtraction therapy of Danggui Shaoyaosan combined with Huaihuasan in the treatment of UC (dampness-heat in large intestine) during active stage can control the disease activity in a short term, promote restoration of the colonic mucosa. And delay the recurrence in a long term, reduce the recurrence rate, regulate ghrelin neurotransmitters and pro-and anti-inflammatory cytokines levels.
